Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2026)

Adaptive Biotechnologies has reported Gross Profit for 9 years, with the latest figure at $52.2 million in Q1 2026.

• Quarterly Gross Profit rose 47.1% year-over-year to $52.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222.3 million (up 87.58% YoY) and the FY2025 annual result came in at $205.6 million, up 92.39% from the prior year.
• Gross Profit eased to $52.2 million in Q1 2026 per ADPT's latest filing, from $53.5 million in the prior quarter.
• Over five years, Gross Profit peaked at $75.8 million in Q3 2025 and troughed at -$10.2 million in Q2 2023.
• A 5-year average of $32.1 million and a median of $29.8 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2024: Gross Profit sank 133.54% in 2023, then surged 333.82% in 2024.
• Over 5 years, Gross Profit stood at $38.6 million in 2022, then tumbled by 32.22% to $26.2 million in 2023, then gained by 12.4% to $29.4 million in 2024, then soared by 81.74% to $53.5 million in 2025, then slipped by 2.42% to $52.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $52.2 million, $53.5 million, and $75.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.